Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
Abstract This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment...
Main Authors: | Yoshio Iwashima, Hiromichi Fukushima, Takeshi Horio, Tatemitsu Rai, Toshihiko Ishimitsu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | The Journal of Clinical Hypertension |
Subjects: | |
Online Access: | https://doi.org/10.1111/jch.14635 |
Similar Items
-
Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
by: Bin Wang, et al.
Published: (2022-03-01) -
The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
by: Cong Zhao, et al.
Published: (2022-11-01) -
Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
by: Reza Mohebi, et al.
Published: (2023-10-01) -
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01) -
Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
by: Yanhong Guo, et al.
Published: (2022-11-01)